J Clin Transl Endocrinol
However, the GLP-1 saga turns out, the fact that these drugs have popped up seemingly out of nowhere, and have generated such excitement, highlights the potential existing in the huge repurposed drug (drugs used in another condition than for which they are approved) market for these diseases
Marre M, Shaw J, Brandle M, et al, for the LEAD-1 SU Study Group
Frontiers in Endocrinology, 16, 1593334
Retatrutide Dosing Schedule: Phase 3 Trial Updates The Phase 3 TRIUMPH trial program is evaluating retatrutide at doses that build on the Phase 2 trial findings
When to Consider Testing Testing may be useful: Before starting a GLP-1 medicine After a meaningful treatment change When diabetes goals are not being met When persistent gastrointestinal symptoms develop When food or fluid intake has significantly decreased When kidney or liver risk is already present When a prior result was abnormal When a healthcare provider recommends follow-up Testing frequency should be based on individual risk rather than an automatic monthly or quarterly panel for everyone
